Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies.
作者信息
Lacroix-Desmazes Sébastien, Pratt Kathleen P
机构信息
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
出版信息
Front Immunol. 2021 Jan 25;11:639386. doi: 10.3389/fimmu.2020.639386. eCollection 2020.
Abstract
摘要
相似文献
1
Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies.
Front Immunol. 2021 Jan 25;11:639386. doi: 10.3389/fimmu.2020.639386. eCollection 2020.
2
Tolerating Factor VIII: Recent Progress.
Front Immunol. 2020 Jan 10;10:2991. doi: 10.3389/fimmu.2019.02991. eCollection 2019.
3
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.
Front Immunol. 2020 Jan 17;10:3078. doi: 10.3389/fimmu.2019.03078. eCollection 2019.
4
Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
Haemophilia. 2014 Nov;20(6):e414-7. doi: 10.1111/hae.12521. Epub 2014 Oct 21.
5
[Origin and nature of the neutralizing immune response against therapeutic factor VIII].
Med Sci (Paris). 2020 Apr;36(4):341-347. doi: 10.1051/medsci/2020060. Epub 2020 May 1.
6
Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.
Blood. 2012 May 31;119(22):5294-300. doi: 10.1182/blood-2011-11-391680. Epub 2012 Apr 12.
7
B cell-activating factor modulates the factor VIII immune response in hemophilia A.
J Clin Invest. 2021 Apr 15;131(8). doi: 10.1172/JCI142906.
8
Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report.
Haemophilia. 2009 Mar;15(2):587-91. doi: 10.1111/j.1365-2516.2008.01944.x.
9
Inhibitory antibodies in hemophilia A.
Curr Opin Hematol. 2012 Sep;19(5):399-405. doi: 10.1097/MOH.0b013e328356ed37.
10
Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?
Haematologica. 2019 Feb;104(2):236-244. doi: 10.3324/haematol.2018.206383. Epub 2018 Dec 4.
引用本文的文献
1
Determination of Rutin's antitumoral effect on EAC solid tumor by AgNOR count and PI3K/AKT/mTOR signaling pathway.
Med Oncol. 2023 Mar 27;40(5):131. doi: 10.1007/s12032-023-01999-7.
本文引用的文献
1
ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study.
Thromb Haemost. 2020 Aug;120(8):1166-1172. doi: 10.1055/s-0040-1713097. Epub 2020 Jun 22.
2
Factor VIII replacement is still the standard of care in haemophilia A.
Blood Transfus. 2019 Nov;17(6):479-486. doi: 10.2450/2019.0211-19. Epub 2019 Dec 11.
3
New therapies for hemophilia.
Blood. 2019 Jan 31;133(5):389-398. doi: 10.1182/blood-2018-08-872291. Epub 2018 Dec 17.
4
The socioeconomic burden of patients affected by hemophilia with inhibitors.
Eur J Haematol. 2018 Oct;101(4):435-456. doi: 10.1111/ejh.13108. Epub 2018 Jul 27.
5
A cold-blooded view of adaptive immunity.
Nat Rev Immunol. 2018 Jul;18(7):438-453. doi: 10.1038/s41577-018-0003-9.
6
Beyond binding: antibody effector functions in infectious diseases.
Nat Rev Immunol. 2018 Jan;18(1):46-61. doi: 10.1038/nri.2017.106. Epub 2017 Oct 24.
7
Signaling by Antibodies: Recent Progress.
Annu Rev Immunol. 2017 Apr 26;35:285-311. doi: 10.1146/annurev-immunol-051116-052433.
8
Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX.
J Clin Med. 2017 Apr 17;6(4):46. doi: 10.3390/jcm6040046.
9
The burden of inhibitors in haemophilia patients.
Thromb Haemost. 2016 Aug 31;116 Suppl 1:S10-7. doi: 10.1160/TH16-01-0049. Epub 2016 Aug 16.
10
Antibody polyreactivity in health and disease: statu variabilis.
J Immunol. 2013 Aug 1;191(3):993-9. doi: 10.4049/jimmunol.1300880.
Zotero 插件